1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. XENON PHARMACEUTICALS INC
Xenon Pharmaceuticals Inc
XNAS: XENE
Download real time
36.41-0.16(-0.44%)
New 52W Low in past week
2.0M
XNAS Volume

XNAS 07 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Xenon Pharma Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Xenon Pharma Inc share price target, revenues, EPS, net income and more

Xenon Pharma Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
  • NEUTRAL

    Quarterly Revenue Xenon Pharma Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of 0% YoY.

  • NEGATIVE

    Quarterly Net Profit Xenon Pharma Inc Jun-2026 Quarterly Net Profit is $-111 Million which is growth of -30.7% YoY.

Xenon Pharmaceuticals Inc, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
7.5
Cost Of Rev.
-------------
Gross Profit
-------------
⌄
123.2112.3109.896.394.280.277.573.769.15953.755.755.6
Operating Profit
-123.2-112.3-109.8-96.3-94.2-72.7-77.5-73.7-69.1-59-53.7-55.7-55.6
⌄
12.16.95.36.27.28.19.410.310.811.48.776.5
Profit Before Tax
-111.3-104.9-104.7-90.2-85.3-64.6-69.5-63.1-58.3-47.5-45-48.6-47.7
Tax
-0.6-2.60.50.7-0.60.4-3.9-0.3-0.30.4-0.2-0.2-0.2
⌄
-110.7-102.3-105.3-90.9-84.7-65.1-65.7-62.8-57.9-47.9-44.7-48.5-47.5
Diluted NI Avail to Com Stockholders Ann.
-110.7-102.3-105.3-90.9-84.7-65.1-65.7-62.8-57.9-47.9-44.7-48.5-47.5
Basic EPS
-1.1-1.2-1.3-1.2-1.1-0.8-0.8-0.8-0.8-0.6-0.6-0.7-0.7
Diluted EPS After ExtraOrdinary
-1.1-1.2-1.3-1.2-1.1-0.8-0.8-0.8-0.8-0.6-0.6-0.7-0.7
Number Of Shares End
99.687.480.179.37978.778.477.977.777.6706665.9
Net Income Continuing Discontinued Operations
-110.7-102.3-105.3-90.9-84.7-65.1-65.7-62.8-57.9-47.9-44.7-48.5-47.5
Normalized Income
-110.4-102.8-105-90.8-86.4-65.1-64.3-63-57.9-48.1-44.8-48.5-48.9
Interest Income
12.16.95.36.27.28.19.410.310.811.48.776.5
Interest
-------------
Net Interest Income
12.16.95.36.27.28.19.410.310.811.48.776.5
EBIT
-123.2-112.3-109.8-96.3-94.2-72.7-77.5-73.7-69.1-59-53.7-55.7-55.6
EBITDA
-122.6-111.7-109.2-95.7-93.6-72.1-76.8-73-68.4-58.4-52.8-54-55
Reconciled Cost Of Rev.
-------------
Reconciled Depr.
0.60.60.60.60.60.70.60.70.70.60.91.70.6
Profit From Continuing Operations
-110.7-102.3-105.3-90.9-84.7-65.1-65.7-62.8-57.9-47.9-44.7-48.5-47.5
Normalized EBITDA
-122.3-112.3-108.9-95.6-95.3-72.1-75.4-73.2-68.5-58.6-52.9-54-56.4
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Xenon Pharma Inc competitor comparison and performance snapshot within industry

Xenon Pharma Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEUTRAL

    Annual Revenue Xenon Pharma Inc Dec-2025 Annual Revenue is $8 Million which is growth of 0% YoY.

  • NEGATIVE

    Annual Net Profit Xenon Pharma Inc Dec-2025 Annual Net Profit is $-346 Million which is growth of -47.6% YoY.

Xenon Pharmaceuticals Inc, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
-7.3%
-25.3%
 7.59.418.432.26.80.31.815.6
Cost Of Rev. Ann.
-
-
 ------6---
Gross Profit Ann.
-
-
 ------6.8-6---
Operating Exp. Ann.
40%
43.1%
441.6380.6279.3214.1138.697.463.549.73232.926.624.9
Operating Profit Ann.
-
-
-441.6-373.1-279.3-214.1-129.1-79-31.3-42.8-38-32.6-24.8-9.4
⌄
45.5%
71.6%
30.626.841.927.68.70.51.80.9-0.20.50.50.5
Other Exp. Ann.
-
28.5%
 1.4-1.13.8-4.8-0.40.40.33.71.41.3-6.9
PBT Ann.
-
-
-411.1-344.9-238.4-182.7-125.3-78.9-29.1-41.6-34.5-30.7-23-15.8
Tax Ann.
115.4%
-
-1.91-4.1-0.30.1-0-0.3-0----
⌄
-
-
-409.2-345.9-234.3-182.4-124.9-77.1-28-40-31.6-30.7-23-15.8
Diluted NI Avail to Com Stockholders Ann.
-
-
-409.2-345.9-234.3-182.4-124.9-77.1-28-40-31.6-30.7-23-15.8
EPS Ann.
-
-
 -4.4-3-2.7-2.1-1.8-0.8-1.5-1.6-1.7-1.5-1.1
Diluted EPS Ann.
-
-
 -4.4-3-2.7-2.1-1.8-0.8-1.5-1.6-1.7-1.5-1.1
Number Of Shares End
6.8%
18%
 80.178.47065.755.73526.425.31817.914.4
Total Exp. Ann.
40%
43.1%
 380.6279.3214.1138.697.463.549.73832.926.624.9
Net Income Continuing Discontinued Operations Ann.
-
-
-409.2-345.9-234.3-182.4-125.4-78.9-28.8-41.6-34.5-30.7-23-15.8
Normalized Income Ann.
-
-
-409.1-347.1-233.3-186.1-121.8-78.5-29.2-41.9-38.2-32.1-24.3-8.8
Interest Income Ann.
45.5%
63.4%
30.626.841.927.68.70.52.32.41.20.50.50.5
Interest Ann.
-
-
 ---0.51.41.4---
EBITDA Ann.
-
-
-439.2-370.5-276.7-210.5-123.6-78-28-39.8-32.5-31.9-24-8.3
Reconciled Cost Of Rev. Ann.
-
-
 ------6---
Reconciled Depr. Ann.
16%
33%
2.42.52.63.51.60.90.60.40.60.70.91
Profit From Continuing Operations Ann.
-
-
-409.2-345.9-234.3-182.4-125.4-78.9-28.8-41.6-34.5-30.7-23-15.8
Normalized EBITDA Ann.
-
-
-439-371.9-275.7-214.3-118.8-77.6-28.4-40-36.2-33.3-25.3-1.4
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Rev. Ann.
3Y CAGR
-7.3%
5Y CAGR
-25.3%
10Y CAGR
-7.1%
Operating Exp. Ann.
1Y CHG
36.3%
2Y CAGR
33.3%
3Y CAGR
40%
5Y CAGR
43.1%
7Y CAGR
42.4%
10Y CAGR
31.3%
Operating Expenses Annual Cr growth is lower than historical averages.

Xenon Pharma Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Total Shareholders Fund Xenon Pharma Inc Dec-2025 Total Shareholders Fund is $582 Million which is growth of -22.9% YoY.

  • NEGATIVE

    Total Assets Xenon Pharma Inc Dec-2025 Total Assets is $633 Million which is growth of -20.7% YoY.

Xenon Pharmaceuticals Inc, Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
-5.7%
27.3%
633.2798.1964.8754.2572189.2147.7122.446.167.564
⌄
16.3%
23.6%
51.443.236.932.72217.855.719.110.23.62.9
⌄
-6.9%
28.9%
581.8754.9927.9721.5542.3163.684.295.635.963.961
Total Capitalization Ann.
-6.9%
27.7%
581.8754.9927.9721.5550171.4102.9118.34263.961
Tangible Assets Ann.
-6.9%
27.7%
581.8754.9927.9721.5550171.492103.335.963.961
Working Capital Ann.
-3.5%
25.5%
518.9599.7617.7577.6544.7167101.5117.340.762.258.1
Invested Capital Ann.
-6.9%
28.9%
581.8754.9927.9721.5542.3163.699.8110.642.763.961
Tangible Book Value Ann.
-6.9%
28.9%
581.8754.9927.9721.5542.3163.684.395.635.963.961
Borrowings Ann.
-8.8%
19.1%
7.9910.910.48.33.316.5156.8--
Net Debt Ann.
-
-
-----------
Share Issued Ann.
8.5%
18%
8076.475.462.651.63528.125.81817.914.4
Number Of Shares End
6.8%
18%
80.178.47065.755.73526.425.31817.914.4
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
-20.7%
2Y CAGR
-19%
3Y CAGR
-5.7%
5Y CAGR
27.3%
7Y CAGR
26.5%
10Y CAGR
25.8%
Total Assets Annual is falling faster than historical averages.
Total Current Liabilities Ann.
1Y CHG
17.4%
2Y CAGR
23.7%
3Y CAGR
22.6%
5Y CAGR
23.1%
7Y CAGR
39.3%
10Y CAGR
31%
Total Current Liabilities Annual Cr growth is lower than historical averages.
Total ShareHolders Funds Ann.
1Y CHG
-22.9%
2Y CAGR
-20.8%
3Y CAGR
-6.9%
5Y CAGR
28.9%
7Y CAGR
29.4%
10Y CAGR
25.3%
Total ShareHolders Funds Annual is falling faster than historical averages.

Xenon Pharma Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Book Value Per Share Xenon Pharma Inc Book Value Per Share is $13 which is growth of 56.0% YoY.

  • NEUTRAL

    ROE Xenon Pharma Inc ROE is 0% which is growth of 0% YoY.

Xenon Pharmaceuticals Inc, Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
RoA Ann. %
-
-
--26.58%-21.22%-18.84%-20.25%-16.63%-29.64%-37.52%-54.05%-34.99%-20.81%
ROE Ann. %
-
-
--27.85%-22.12%-19.77%-21.84%-22.60%-44.52%-48.09%-61.51%-36.81%-23.54%
ROIC %
-
-
--9.5-6.7-5.5-6.4-7.1-12-7.6---
OPM Ann. %
-
-
-4,974.27%---1,368.91%-428.45%-97.31%-627.02%--10,474.28%-1,376.43%-60.10%
Inventory Turnover Ratio Ann.
-
-
-----------
Asset Turnover Ann. %
-
-
---00.10.20.1-000.2
Working Capital Turnover Ann.
-
-
0000.20.1000.3
Quick Ratio Ann.
-
-
-17.723.426.138.712.13.32910.818.321.2
Current Ratio Ann.
-
-
-17.923.726.43912.33.329.51118.721.9
Interest Coverage Ratio Ann.
-
-
------59.1-28-23.8---
LT Debt To Equity Ann.
-
-
-000000.10.20.2--
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Xenon Pharma Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Cash From Operating Activity Xenon Pharma Inc Dec-2025 Cash From Operating Activity is $-279 Million which is growth of -53.9% YoY.

  • POSITIVE

    Net Cash Flow Xenon Pharma Inc Dec-2025 Net Cash Flow is $56 Million which is growth of 1414.7% YoY.

Xenon Pharmaceuticals Inc, Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
-
-
-279.1-181.4-145.3-98.4-69.5-48.1-4.6-34.7-28.7-19.6-18.1
⌄
-
-
218165-117.2-296-246.8-16.8-66.3-2924.3-47.810.2
⌄
-25.1%
6.4%
117.112.1353.5278.5447.585.827.5111.67.1240.3
Cash Plus Cash Eqv. End Of Year Ann.
51.6%
34.7%
199.2142.7148.657.2175.74524.867.820.517.158.7
Net Increase In Cash Plus Cash Eqv.s Ann.
-
21.8%
56-4.391-116131.320.9-43.447.92.6-43.4-7.6
Cash Plus Cash Eqv. Begin Of Year Ann.
-6.7%
41.9%
142.7148.657.2175.74524.867.820.517.158.772
Income Tax Paid Supplemental Data Ann.
-
-
-----------
Interest Paid Supplemental Data Ann.
-
-
---0.30.90.6---
Capex Ann.
-
-
-0.8-3.1-5.6-2.9-2.1-2.6-1.2-0.5-0.3-0.3-0.6
Issuance Of Capital Stock Ann.
-26.1%
1.8%
112.212.1353.5277.8447.3102.527.4102.923.80.3
Issuance Of Debt Ann.
-
-
------8.56.9--
Repayment Of Debt Ann.
-
-
----16.7-----
Repurchase Of Capital Stock Ann.
-
-
-----------
Free Cash Flow Ann.
-
-
-279.9-184.5-150.9-101.3-71.6-50.8-5.9-35.2-29-19.9-18.7
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Investing Act. Ann.
1Y CHG
32.1%
10Y CAGR
35.8%
Cash from Investing Activity Annual growth is lower than historical averages.
Cash from Financing Act. Ann.
1Y CHG
867.8%
2Y CAGR
-42.4%
3Y CAGR
-25.1%
5Y CAGR
6.4%
7Y CAGR
0.7%
10Y CAGR
81.6%
Cash from Financing Annual Activity growth is higher than historical averages.
×